Items tagged with Treatment
Contact with MDR-TB led to latent infection in some children (post)
After contact with a teacher diagnosed with multidrug-resistant pulmonary tuberculosis, 31 children developed latent infection, according to recent study results published in The Pediatric Infectious Disease Journal.
A metabolic biosignature of early response to anti-tuberculosis treatment (post)
Abstract (provisional)
Critical Path Institute receives grant to accelerate development of TB treatments (post)
TUCSON, Ariz., Feb. 4, 2014 /PRNewswire-USNewswire/ -- The Critical Path Institute, an independent, non-profit that catalyzes innovative ideas that accelerate the speed of drug and medical product development, today announced it has received a three-year grant from the Bill & Melinda Gates Foundation. The grant will be used to develop quantitative mathematical models to optimize the design of clinical trials and tackle challenges facing the development of effective tuberculosis (TB) treatments.
Poor survival with XDR TB in South Africa, but ART improves survival (post)
Three quarters of South African patients with extensively drug-resistant (XDR) tuberculosis died within 5 years of treatment, according to results of a 107-patient analysis in three South African provinces. Among people with HIV infection, taking antiretroviral therapy (ART) was independently associated with survival.
TB therapy has no effect on virologic or CD4 response to ART (post)
People being treated for tuberculosis achieved virologic and CD4 responses to antiretroviral therapy (ART) similar to people not being treated for TB, according to results of a 25-study systematic review and meta-analysis.
Treating tuberculosis and AIDS together saves lives (post)
Patients who have multi-drug-resistant tuberculosis and are more likely to live if they get simultaneous treatment for both diseases rather than waiting weeks to start the AIDS treatment, a new study has found.
13-country trial finds low-dose efavirenz as effective as standard (post)
Virologic response at 48 weeks was similar with 400 mg of efavirenz daily and the standard 600 mg daily in a double-blind randomized trial involving antiretroviral-naive people in 13 countries across the world. Safety was better with the lower dose.
Zimbabwe PHC clinics cascade TB-HIV care successfully: The story of Phakama Clinic (post)
Phakama Clinic is one of the 23 urban clinics supported since 2012 through The Union’s TB CARE project in 17 urban areas of Zimbabwe. Located in a high-density suburb of the City of Gwanda, provincial capital of Matabeleland South Province, Phakama Clinic is the only one participating in the project that is run by the local authority.
Breakthrough against drug-resistant TB (post)
Cape Town - Local tuberculosis experts are optimistic that a novel TB antibiotic, which is being tested on multidrug-resistant TB sufferers in a Cape Town hospital, could revolutionise treatment of the killer disease.
Rifapentine, moxifloxacin active as part of shorter TB regimen (post)
BOSTON — A shorter treatment regimen consisting of rifapentine, moxifloxacin, isoniazid and pyrazinamide was more active than a control regimen against drug-susceptible pulmonary tuberculosis, researchers reported at the 2014 Conference on Retroviruses and Opportunistic Infections.
Page 2 of 108 · Total posts: 0
←First 1 2 3 Last→